Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BLINK AG currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is being handled by 1 distinct examiner in 1 distinct art unit. This indicates a very specific and narrow focus for the company's current patent prosecution efforts, as there is no current distribution across different examiners or administrative groups.
The busiest examiner for the company is HOPPE, EMMA RUTH, who is responsible for 1 pending office action. Since there is only 1 pending office action in total, the busiest examiner pending count of 1 covers the company's entire active portfolio. Practitioners can see that the company's current results are tied to the performance of this single examiner. This means that the prosecution strategy for BLINK AG is currently centralized under the review of HOPPE, EMMA RUTH.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 40.0% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786033 | A METHOD OF DETECTING AND/OR QUANTITATING AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES | HOPPE, EMMA RUTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786033 | A METHOD OF DETECTING AND/OR QUANTITATING AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17786033 | A METHOD OF DETECTING AND/OR QUANTITATING AN ANALYTE OF INTEREST IN A PLURALITY OF BIOLOGICAL LIQUID SAMPLES | HOPPE, EMMA RUTH | 1683 | §103§112Other | Final Rejection | — | Pending | Jun 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBLINK AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emma Ruth Hoppe has the most, with 1 of BLINK AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
